Literature DB >> 10128127

The trade-off between severity of illness and treatment effect in cost-value analysis of health care.

E Nord1.   

Abstract

Social appreciation of health care programs is a function of the severity of the patients' initial state as well as of treatment effect. Prioritising on the basis of cost-per-QALY misses the former point. The trade-off between severity and treatment effect can be expressed in terms of equivalence of numbers for different outcomes. The present study suggests that this trade-off can be modeled mathematically with reasonable accuracy. A table that expresses social equivalence numbers as a function of severity and treatment effect could be used together with guidelines for adjusting for age, duration and risk to estimate the social value of any outcome. In this valuation, saving a young person from dying to a life as healthy (= 1 SAVE) is suggested as the unit of measurement. Cost per SAVE may then be useful as a guiding criterion in prioritising.

Entities:  

Mesh:

Year:  1993        PMID: 10128127     DOI: 10.1016/0168-8510(93)90042-n

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  36 in total

Review 1.  Valuing health-related quality of life. A review of health state valuation techniques.

Authors:  C Green; J Brazier; M Deverill
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

2.  Severity as an independent determinant of the social value of a health service.

Authors:  Jeff R J Richardson; John McKie; Stuart J Peacock; Angelo Iezzi
Journal:  Eur J Health Econ       Date:  2010-05-09

Review 3.  Resource allocation, social values and the QALY: a review of the debate and empirical evidence.

Authors:  David L B Schwappach
Journal:  Health Expect       Date:  2002-09       Impact factor: 3.377

4.  QALYs: maximisation, distribution and consent. A response to Alan Williams.

Authors:  P T Menzel
Journal:  Health Care Anal       Date:  1995-08

5.  Towards cost-value analysis in health care?

Authors:  E Nord
Journal:  Health Care Anal       Date:  1999

6.  The value of thinly spread QALYs.

Authors:  Duncan Mortimer
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

7.  Orphan drugs for rare diseases: is it time to revisit their special market access status?

Authors:  Steven Simoens; David Cassiman; Marc Dooms; Eline Picavet
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

8.  Expensive cancer drugs: a comparison between the United States and the United Kingdom.

Authors:  Ruth R Faden; Kalipso Chalkidou; John Appleby; Hugh R Waters; Jonathon P Leider
Journal:  Milbank Q       Date:  2009-12       Impact factor: 4.911

9.  Cost-value analysis of health interventions: introduction and update on methods and preference data.

Authors:  Erik Nord
Journal:  Pharmacoeconomics       Date:  2015-02       Impact factor: 4.981

Review 10.  Orphan drugs policies: a suitable case for treatment.

Authors:  Michael Drummond; Adrian Towse
Journal:  Eur J Health Econ       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.